Education
About Us
Working with TipRanks
Follow Us
Sanofi (FR:SAN)
:SAN
Earnings Data
Report Date
Apr 24, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.68Last Year’s EPS
1.78Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: 2.85%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, especially in Dupixent and the Vaccine business, supported by new product launches and improved financial metrics. However, challenges were noted in exchange rates, potential tariffs, and specific segments like respiratory development and the U.S. flu vaccine market.Company Guidance
During the Q1 2025 Sanofi conference call, CEO Paul Hudson announced a strong start to the year with a 7% sales growth driven by new pharma launches. Dupixent achieved a 20% sales increase, reaching €3.5 billion, while new product launches contributed €1.1 billion in sales. The company obtained FDA approval for QFIPIA in hemophilia and aims for continued growth with upcoming regulatory decisions. François-Xavier Roger, CFO, reported a 9.7% increase in net sales to €9.9 billion, with a gross margin improvement to 78%. Business EPS rose 15.7% to €1.79. Sanofi plans a €5 billion share buyback, with 76% completed. The company maintains a focus on organic growth, evaluating bolt-on acquisitions, and expects a stable tax rate around 20% for 2025.Strong Start to 2025 with Sales Growth
Sanofi reported a 7% sales growth in Q1 2025, driven by pharma launches and vaccines, with new launches generating EUR 1.1 billion in sales, contributing 11% of the total.
Dupixent Growth and U.S. Market Performance
Dupixent delivered a 20% growth in Q1, reaching EUR 3.5 billion in sales, with EUR 2.5 billion from the U.S., up 18%. Dupixent leads total prescription share across all approved indications.
Vaccine Business Double-Digit Growth
Sanofi's Vaccine business delivered double-digit growth in Q1, driven by favorable Fortis phasing and new country launches. Manufacturing for flu vaccines is progressing as planned.
Improved Financial Metrics
Gross margin improved to 78%, up 2.3 percentage points from the previous year. Business EPS was EUR 1.79, up 15.7%, reflecting strong sales performance and improved operating leverage.
Innovative Pipeline Progress
Sanofi obtained 6 approvals in Q1, including Sarclisa and Dupixent in new indications, and announced the acquisition of DR 0201 from Dren Bio to strengthen its pipeline in immunology.
---
FR:SAN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FR:SAN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 24, 2025 | €93.24 | €93.35 | +0.12% |
| Jan 30, 2025 | €101.86 | €103.62 | +1.73% |
| Oct 25, 2024 | €97.60 | €100.08 | +2.54% |
| Jul 25, 2024 | €93.57 | €97.49 | +4.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sanofi (FR:SAN) report earnings?
Sanofi (FR:SAN) is schdueled to report earning on Apr 24, 2025, TBA Not Confirmed.
What is Sanofi (FR:SAN) earnings time?
Sanofi (FR:SAN) earnings time is at Apr 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sanofi stock?
The P/E ratio of Sanofi is N/A.
What is FR:SAN EPS forecast?
FR:SAN EPS forecast for the fiscal quarter 2025 (Q1) is 1.68.
---